Synthetic PPAR-α and PPAR-γ agonists not only regulate expressions of genes involving lipid and glucose metabolism, but also modulate mitochondrial function and therefore appear to be promising treatments for diabetic cardiomyopathy. The gene discussed is PPARG; the disease is diabetic cardiomyopathy.